Modality
ADC
MOA
VEGFi
Target
IL-13
Pathway
DDR
MDS
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Sep 2030
Phase 2Current
NCT05398182
968 pts·MDS
2021-12→2026-11·Completed
NCT04480281
2,092 pts·MDS
2017-01→2030-09·Recruiting
3,060 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-017mo awayPh2 Data· MDS
2030-09-134.5y awayPh2 Data· MDS
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Recruit…
P2
Complet…
Catalysts
Ph2 Data
2026-11-01 · 7mo away
MDS
Ph2 Data
2030-09-13 · 4.5y away
MDS
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05398182 | Phase 2 | MDS | Completed | 968 | ACR20 |
| NCT04480281 | Phase 2 | MDS | Recruiting | 2092 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |